Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 51.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 73,858 shares of the biopharmaceutical company’s stock after selling 77,738 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.13% of Vanda Pharmaceuticals worth $354,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VNDA. Verition Fund Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Vanda Pharmaceuticals by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. Franklin Resources Inc. raised its stake in Vanda Pharmaceuticals by 8.8% during the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 4,449 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Tuesday, February 25th. The shares were bought at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the acquisition, the chief executive officer now owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This trade represents a 0.43 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.90% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright raised their price objective on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th.

Vanda Pharmaceuticals Trading Up 2.5 %

NASDAQ:VNDA opened at $4.46 on Wednesday. The stock has a market cap of $260.09 million, a P/E ratio of -13.94 and a beta of 0.74. The stock has a 50 day simple moving average of $4.59 and a 200 day simple moving average of $4.81. Vanda Pharmaceuticals Inc. has a 1-year low of $3.71 and a 1-year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.